# Cancer burden and trends in China: A review and comparison with Japan and South Korea

#### Dianqin Sun, Maomao Cao, He Li, Siyi He, Wanqing Chen

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China

Correspondence to: Wanqing Chen. National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China. Email: chenwq@cicams.ac.cn.

#### Abstract

**Objective:** To summarize the cancer burden and trends in China, compare the differences among China, Japan, and South Korea and discuss possible causes of the disparities.

**Methods:** Incidence and mortality data were extracted from the online cancer database including the GLOBOCAN 2018 and the Global Burden of Disease Study 2017. Trend analysis was conducted using the join-point analysis, and annual percent changes were calculated.

**Results:** Cancers resulted in approximately 62.9 million disability-adjusted life years (DALYs) in China in 2017. Lung cancer had the greatest contribution, followed by liver cancer, stomach cancer, and esophageal cancer. The trajectory of progress in the reduction of liver and stomach cancers was observed in China. However, China still faced a heavy burden of lung cancer and a growing burden of cancers related to westernized lifestyle such as colorectal cancer, while Japan and South Korea have achieved reductions in colorectal cancer and lung cancer, respectively. Besides, China had a lower age-standardized cancer incidence rate but higher cancer mortality and DALY rates than Japan and South Korea.

**Conclusions:** China is in the cancer transition stage with a rising burden of colorectal, prostate, and breast cancers along with a heavy burden of lung and upper digestive tract cancers. Taking into consideration the effectiveness of screening and tobacco control in Japan and South Korea, improvement in the current tobacco control policy and cancer screening systems may contribute to cancer control in China.

Keywords: Cancer burden; trend; China; comparison

Submitted Feb 28, 2020. Accepted for publication Mar 10, 2020. doi: 10.21147/j.issn.1000-9604.2020.02.01 View this article at: https://doi.org/10.21147/j.issn.1000-9604.2020.02.01

## Introduction

Cancer is the leading cause of death worldwide (1). Distinct geographic disparities exist in cancer burden across the world (2). China, Japan, and South Korea are all located in East Asia. As neighboring countries, Japan and South Korea share similar genetic backgrounds and similar culture with China. Also, in terms of cancer burden, these three countries are all facing a heavy burden of upper digestive tract cancers. But China, Japan, and South Korea are at different stages of socio-economic development. Japan and South Korea are ahead of China in industrialization and urbanization and have higher incidence rates of some westernized lifestyle-related cancers, such as breast cancer and colorectal cancer (3). Besides, Japan and South Korea have a longer history of nationwide cancer control programs than China (4,5). Comparison among these three countries for the cancer burden and trends could be useful to track the effectiveness of national screening programs and to identify modifiable risk factors. The results can serve as a scientific reference for cancer control policy planning. Thus, we sought to provide an overview of cancer burden and trends in China and to compare them with those in Japan and South Korea. Considering the credibility, availability, and comparability of data, we conducted the analysis based on the online cancer database from the GLOBOCAN 2018 (6) and the Global Burden of Disease Study 2017 (GBD 2017) (7) and we also reviewed cancer survival data from the CONCORD-3 (8), cancer registry reports from China (9,10), Japan (11,12), and South Korea (5,13). We hope that this comparative analysis could contribute to improving measures of cancer control in China.

# **Materials and methods**

#### Data sources

National estimates of age-standardized incidence and mortality for China, Japan, and South Korea in 2018 were obtained from the GLOBOCAN 2018 (6). The GLOBOCAN project initiated by the International Agency for Research on Cancer (IARC) systematically quantified the incidence, mortality, and prevalence in 185 countries or territories for 36 cancer types. The projected national rates for China in the GLOBOCAN 2018 were based on the recent data from 92 cancer registries. Observed national rates, including incidence and mortality in South Korea, and mortality in Japan, were available and applied to predict the corresponding rates in 2018. Incidence rates in Japan were estimated using mortality-to-incidence ratios derived from cancer registries (14). For the trend analysis, we referred to the cancer incidence in five continents (CI5) series (15). The incidence data in CI5 series were derived from high-quality national population-based registries including five registries in China, five in South Korea and four in Japan. All age-standardized rates of incidence and mortality were calculated using the world standard population. Cancer survival data were retrieved from the CONCORD-3 (8), which provides the largest and latest international cancer survival data. Age-standardized fiveyear survival rates were calculated using the International Cancer Survival Standard weights (16).

Disability-adjusted life years (DALYs) attributable to cancers for China, Japan, and South Korea in 1990 and 2017 were retrieved from the GBD online results tool (7) engineered by the Institute for Health Metrics and Evaluation (IHME). The GBD annually provides age-sexspecific DALYs for countries across the world. Detailed methods for the GBD 2017 study have been reported in previous studies (17,18). In this study, DALYs per 100,000 population estimates for 29 cancer sites in China, Japan, and South Korea in 2017 were presented by sex and age. To reflect the trends of cancer burden, we also showed the percentage change in all-age and age-standardized DALY rates in China, Japan, and South Korea from 1990 to 2017. The age-standardized DALY rates were based on the GBD reference population (18).

# Statistical analysis

Join-point models were used (19) to examine the time trends in age-standardized incidence rates for selected cancer sites in China, Japan, and South Korea. We applied the logarithmic transformation of the rates and a maximum number of two join-points (three line segments) in the models. The annual percent change (APC) was calculated to indicate the direction and magnitude of the trends. The term "increase" or "decrease" was used if the APC was statistically different from zero. P<0.05 was considered statistically significant. The trend analysis was conducted by Joinpoint Regression Program (V.4.7.0.0, National Cancer Institute, 2019).

# Results

#### Current cancer burden in China

According to the estimates by the GLOBOCAN 2018, about 4,285,033 new cancer cases were diagnosed in China in 2018, which included 2,366,010 males and 1,919,023 females. The crude and age-standardized incidence rates (ASIR) for all cancers were 301.1 and 201.7 per 100,000, respectively. An estimated 2,865,174 cancer deaths occurred in 2018, with 1,791,805 deaths occurring in males and 1,073,369 in females. The crude and age-standardized mortality rates (ASMR) were 201.3 and 130.1 per 100,000, respectively. The incidence and mortality rates were higher in males than in females. Table 1 and Figure 1 show that breast cancer has the highest ASIR in both sexes combined, followed by lung cancer, colorectal cancer, and stomach cancer. Lung cancer was the leading cause of cancer death, followed by stomach cancer, liver cancer, and esophageal cancer.

Table 2 shows all age and age-standardized DALYs per 100,000 populations in China in 2017. The GBD 2017 estimated that cancers resulted in approximately 62.9 million DALYs in China. Lung cancer had the greatest

Index	Condor	All					Ra	ank				
Index	Gender	cancers	1st	2nd	3rd	4th	5th	6th	7th	8th	9th	10th
Incidence	Both	201.7	Breast	Lung	Colorectum	Stomach	Liver	Esophagus	Cervix uteri	Thyroid	Prostate	Corpus uteri
			36.1	35.1	23.7	20.7	18.3	13.9	10.7	10.1	9.1	7.1
	Male	223.0	Lung	Stomach	Colorectum	Liver	Esophagus	Prostate	Pancreas	Bladder	Leukemia	NHL
			47.8	29.5	28.1	27.6	19.7	9.1	6.2	5.9	5.8	4.8
	Female	182.6	Breast	Lung	Colorectum	Thyroid	Stomach	Cervix uteri	Liver	Esophagus	Corpus uteri	Ovary
			36.1	22.8	19.4	15.8	12.3	10.7	9.0	8.2	7.1	5.3
Mortality	Both	130.1	Lung	Stomach	Liver	Esophagus	Colorectum	Breast	Pancreas	Prostate	Cervix uteri	Leukemia
			30.9	17.5	17.1	12.7	10.9	8.8	4.9	4.7	4.4	3.5
	Male	166.6	Lung	Liver	Stomach	Esophagus	Colorectum	Pancreas	Prostate	Leukemia	Brain, CNS	NHL
			43.4	25.6	25.0	18.2	13.1	5.6	4.7	4.4	3.6	2.8
	Female	95.2	Lung	Stomach	Colorectum	Breast	Liver	Esophagus	Cervix uteri	Pancreas	Ovary	Brain, CNS
			19.0	10.4	8.8	8.8	8.6	7.4	4.4	4.2	2.9	2.8

Table 1 Age-standardized cancer incidence and mortality rates per 100,000 populations by gender in China in 2018

CNS, central nervous system; NHL, non-Hodgkin lymphoma. The estimates are from Global Cancer Observatory 2018, IARC, 2018 (6). Age-standardized rates are calculated using the direct method and the world standard population.



Figure 1 Age-standardized incidence and mortality rates per 100,000 populations of selected types of cancers in China (red), Japan (green), and South Korea (blue) in 2018. The data used to generate this figure were from the GLOBOCAN database (6).

contribution (24.3%) to the cancer DALY burden in China in 2017, followed by liver cancer (17.7%), stomach cancer (12.4%), and esophageal cancer (7.1%). These four cancer types accounted for more than 60% of cancer DALYs in

China. *Figure 2* illustrates the etiologic constituent of DALYs by age and sex. Leukemia dominated among the youth (<20 years), but brain and nervous system cancer was also an important cancer among young age groups. For

Indox	Gondor	All					F	Rank				
Index	Gender	cancers	1st	2nd	3rd	4th	5th	6th	7th	8th	9th	10th
All age rates	Both	4,450.2	Lung	Liver	Stomach	Esophagus	Colorectum	Breast	Leukemia	Other	Brain, CNS	Pancreas
			1,079.9	789.6	553.3	316.1	301.2	186.8	163.2	143.2	138.7	133.9
	Male	5,607.2	Lung	Liver	Stomach	Esophagus	Colorectum	Leukemia	Brain, CNS	Other	Pancreas	Prostate
			1,479.7	1,195.4	758.1	469.8	356.7	187.4	162.5	159.9	153.1	122.2
	Female	3,243.2	Lung	Breast	Liver	Stomach	Colorectum	Cervical	Esophagus	Leukemia	Other	Brain, CNS
			662.7	370.4	366.3	339.6	243.3	194.1	155.8	137.9	125.9	113.9
Age- standardized rates	Both	3,257.9	Lung	Liver	Stomach	Esophagus	Colorectum	Leukemia	Breast	Other	Brain, CNS	Pancreas
			757.6	552.1	391.7	222.6	216.2	171.0	130.6	126.1	124.6	94.3
	Male	4,202.8	Lung	Liver	Stomach	Esophagus	Colorectum	Leukemia	Brain, CNS	Other	Pancreas	Prostate
			1,075.4	852.4	553.7	341.2	265.5	194.2	146.1	136.2	111.3	101.6
	Female	2,344.3	Lung	Breast	Liver	Stomach	Colorectum	Leukemia	Cervical	Other	Esophagus	Brain, CNS
			451.8	253.0	251.6	235.5	168.9	146.6	132.3	117.9	107.6	102.3

DALYs, disability-adjusted life years; CNS, central nervous system; Other, other malignant neoplasms. The estimates are from the Institute for Health Metrics and Evaluation (IHME) website (7). Age-standardized rates are calculated using the GBD reference population (18).

young and middle-aged adult males, liver cancer and lung cancer were the leading causes of DALYs. Breast cancer resulted in the greatest part of the DALY burden among young and middle-aged adult females. Among elderly adults (>50 years), lung cancer and liver cancer represented the highest disease burden for each sex separately and combined.

# Time trends in China

Table 3 shows that the ASIR for all cancers in females was stable from 1998 to 2012 in China. But a significant downward trend was observed in males during this period. As is shown in *Figure 3*, the ASIR of lung cancer held steady in both sexes since 2009. Upward trends in the ASIR were observed for colorectal cancer, prostate cancer, and thyroid cancer in males and breast cancer in females. In contrast, the ASIR of stomach cancer, esophageal cancer, and liver cancer showed significant declines for each sex.

Figure 4A shows the DALYs of 29 cancer types in China, ranked by the number of DALYs in 2017. Lung cancer became the leading cause of DALYs in 2017, replacing liver cancer in 1990. All-age and age-standardized DALY rates of stomach cancer have decreased by 10.7% and 50.3% since 1990, leading to a decrease in its ranking from the second to the third. Esophageal cancer was still the fourth leading cancer for all-cause DALYs, even though the age-standardized DALY rate decreased by 50.1% over the last

27 years. Colorectal cancer and breast cancer both increased in the ranking to become the fifth and sixth leading cancers of all-age DALYs. The all-age DALYs rates increased for colorectal cancer (69.8%) and breast cancer (64.9%) from 1990 to 2017. The all-age and agestandardized DALY rates have increased substantially for pancreatic cancer, ovarian cancer, and lip and oral cavity cancer since 1990. Age-standardized DALY rate of uterine cancer declined by 53% over this period, leading it from 14th in 1990 to fall outside the top 20 causes in 2017.

# Comparison with Japan and South Korea in current burden

As estimated by the GLOBOCAN 2018, there was a marked variation in cancer incidence rates among China, Japan, and South Korea, with the incidence in Japan and South Korea being higher than that in China. Overall, the ASIR per 100,000 in South Korea observed among males (332.1) and females (310.6) were nearly 1.5 times higher than the rates among males (223.0) and females (182.6) in China. In contrast to incidence rates, mortality rates in China were nearly 1.5 times higher than those in Japan and South Korea within each sex.

Table 1 and Supplementary Table S1 show the top ten cancer types by the ASIR and ASMR for males, females, and combined in China, Japan, and South Korea. Lung cancer, stomach cancer, and colorectal cancer were listed in

	- 45° 3'41		Chi	na						an an		un Jupan			South K	<pre>(orea</pre>		
Sites	Tre	end 1	Tren	id 2	Tren	d 3	Trend	11	Trene	d 2	Trenc	3	Trenc	-	Trend	d 2	Trenc	13
	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC	Years	APC
Male																		
All cancers <sup>†</sup>	1998– 2012	-0.8*					1998– 2002	-1.3*	2002- 2010	1.6*			1999– 2012	1.3*				
Lung	1998– 2000	0.8	2000- 2009	-2.5*	2009– 2012	-0.3	1998– 2005	-0.4	2005– 2010	1.3*			1999– 2012	-1.4*				
Liver	1998– 2012	-1.9*					1998– 2010	-4.6*					1999– 2012	-2.2*				
Stomach	1998– 2000	1.0	2000- 2006	-4.4*	2006– 2012	-2.5*	1998– 2003	-2.7*	2003- 2010	0.8			1999– 2012	-0.3				
Esophagus	1998– 2012	-3.8*					1998– 2010	0.8*					1999– 2002	-0.2	2002– 2006	-5.6*	2006- 2012	0.5
Colorectum	1998– 2012	0.7*					1998– 2010	0.5*					1999– 2009	5.8*	200 <del>9</del> - 2012	0.3		
Prostate	1998– 2002	10.1*	2002- 2012	4.6*			1998– 2010	8.7*					1999– 2012	10.3*				
Thyroid	1998– 2000	-7.9	2000- 2008	9.1*	2008- 2012	22.9*	1998– 2002	-2.3	2002- 2010	8.2*			1999– 2001	7.6	2001– 2009	27.9*	2009- 2012	12.9*
Female																		
All cancers <sup>†</sup>	1998– 2000	3.1	2000- 2009	0	2009– 2012	2.9	1998– 2003	0.1	2003- 2010	3.1*			1999– 2003	2.2	2003- 2012	5.7*		
Lung	1998– 2012	-0.2					1998– 2005	0.5	2005– 2010	3.8* 3.8			1999– 2003	-2.9*	2003– 2012	2.4*		
Liver	1998– 2012	-2.1*					1998– 2010	-3.3*					1999– 2012	-2.2*				
Stomach	1998– 2012	-3.1*					1998– 2003	-3.4*	2003– 2010	0.4			1999– 2012	-0.4				
Esophagus	1998– 2012	-6.1*					1998– 2010	2.2*					1999– 2012	-2.5*				
Colorectum	1998– 2001	2.0	2001– 2012	-0.6*			1998– 2010	÷					1999– 2008	4.4*	2008– 2012	1.5		
Breast	1998– 2000	8.3	2000- 2009	1.6*	2009– 2012	4.5*	1998– 2010	4.2*					1999– 2012	5.7*				
Thyroid	1998– 2003	3.7*	2003- 2012	12.7*			1998– 2002	-4.2*	2002– 2006	11.2*	2006– 2010	4.2	1999– 2009	23.8*	200 <del>9</del> - 2012	10.1		
APC. annual percent	age chang	te; APC	is calculate	d using ac	ae-standai	dized inc	idence dat	a based	on the wo	rld standa	rd populat	ion: *. Th	e APC is ;	sianificant	lv differer	nt from ze	°o (P<0.05	(i): †. All

cancers exclude non-melanoma skin.

www.cjcrcn.org



**Figure 2** Disability-adjusted life years (DALYs) per 100,000 populations attributable to cancers by age and gender in China (A), Japan (B), and South Korea (C) in 2017. The estimates used to generate this figure were from the Institute for Health Metrics and Evaluation (IHME) website (7).



**Figure 3** Trends in age-standardized incidence rates by cancer site and gender (triangle for male; circle for female) in China (red), Japan (green), and South Korea (blue). The data used to generate this figure were from the Cancer Incidence in Five Continents database (15).

the top five common cancers for males in each country. For females, breast cancer, lung cancer, colorectal cancer, stomach cancer, and thyroid cancer were common cancers in the three countries. Figure 1 illustrates the ASIR and ASMR of selected types of cancers in China, Japan, and South Korea in 2018. South Korea had a much higher thyroid cancer incidence than Japan and China. Also, Japan and South Korea had higher incidence rates of breast, colorectal and prostate cancers than China. But the mortality rates of thyroid, breast, colorectal and prostate cancers were similar in these three countries. Another notable aspect was that China had a lower incidence rate but a higher mortality rate of stomach cancer than Japan and South Korea. Correspondingly, Table 4 indicates that Chinese cancer patients had lower 5-year survival rates. Especially for stomach cancer, the survival rate in South Korea has achieved 68.9% but its counterpart was less than 36% in China.

Supplementary Table S2 shows all age and agestandardized DALYs rates in Japan and South Korea in 2017. Age-standardized DALY per 100,000 populations for all cancers was higher in China when compared with Japan and South Korea. *Figure 2* shows DALYs per 100,000 populations by age and gender in China, Japan, and South Korea in 2017. Evaluating DALYs by age, we could see that the population with the highest rates of cancer burden in China were younger than those in Japan and South Korea. Lung cancer represented the highest cancer burden for the three countries, followed by gastrointestinal and liver cancers. In terms of the composition of DALYs by age and sex, leukemia was the highest DALY group among the youth in the three countries, followed by brain and nervous system cancer. For young and middle-aged adult males, the largest contributors to DALYs were liver cancer in China and South Korea and colorectal cancer in Japan, respectively. Breast cancer was the leading cause of DALY among young and middle-aged adult females in the three countries. Among elderly adults (>50 years) in the three countries, lung cancer was the top contributor to cancer burden for males, females, and combined, except being replaced with colorectal cancer in Japanese females.

#### Comparison with Japan and South Korea in time trends

*Figure 3* shows trends in ASIR by cancer site and gender in China, Japan, and South Korea. In contrast to China, upward trends of ASIR in Japan and South Korea were observed. Rising prostate and female breast cancers contributed the greatest part to the increase of all cancers incidence rates. Lung cancer incidence rate remained generally high in China, Japan, and South Korea. Lung cancer jumped to the first cause of DALYs in 2017, replacing live cancer in China, stomach cancer in Japan and

Table 4 Age-standardized 5-year survival rates (%) with 95% CI in adults aged 15–99 years from 2000 to 2014 in China, Japan, and South Korea

Country	Vaara				:	5-year surviva	l rate (95% CI	)			
Country	rears	Lung	Stomach	Liver	Esophagus	Colon	Rectum	Breast	Pancreas	Prostate	Cervix uteri
China	2000-2004	18.7	30.2	11.7	22.9	51.4	49.5	75.9	14.4	57.7	53.3
		(18.0–19.4)	(29.3–31.1)	(10.9–12.5)	(22.0–23.9)	(49.6–53.3)	(47.5–51.4)	(70.9–80.9)	(12.8–16.0)	(52.3–63.0)	(48.1–58.5)
	2005–2009	17.7	33.2	11.6	27.1	55.6	52.5	80.4	10.2	62.5	63.0
		(17.4–18.1)	(32.7–33.7)	(11.1–12.0)	(26.5–27.7)	(54.6–56.5)	(51.5–53.6)	(79.3–81.5)	(9.4–11.0)	(59.9–65.1)	(61.2–64.9)
	2010-2014	19.8	35.9	14.1	29.7	57.6	56.9	83.2	9.9	69.2	67.6
		(19.4–20.2)	(35.3–36.5)	(13.6–14.7)	(29.0–30.4)	(56.6–58.6)	(55.8–58.0)	(82.1–84.3)	(9.1–10.7)	(66.4–72.0)	(65.8–69.5)
Japan	2000-2004	29.3	50.5	25.7	27.7	63.4	58.6	85.9	6.9 (6.4–7.4)	85.9	67.5
		(28.1–30.5)	(50.0–50.9)	(25.1–26.3)	(26.4–29.0)	(62.7–64.0)	(57.6–59.5)	(85.2–86.6)		(84.9–87.0)	(66.3–68.7)
	2005-2009	29.3	57.6	28.6	33.3	66.8	64	88.9	7.6 (7.2–7.9)	91.4	69.2
		(28.9–29.7)	(57.3–57.9)	(28.1–29.1)	(32.3–34.2)	(66.3–67.3)	(63.3–64.6)	(88.4–89.3)		(90.8–92.0)	(68.3–70.1)
	2010-2014	32.9	60.3	30.1	36.0	67.8	64.8	89.4	8.3 (7.8–8.7)	93.0	71.4
		(32.3–33.4)	(59.9–60.7)	(29.5–30.6)	(34.8–37.3)	(67.3–68.4)	(64.0–65.7)	(88.9–89.9)		(92.4–93.6)	(70.4–72.3)
South	2000–2004	15.3	48.6	15.3	18.6	60.5	60.8	79.5	7.6 (7.2–8.1)	76.0	76.0
Korea		(15.0–15.6)	(48.2–48.9)	(15.0–15.7)	(17.6–19.6)	(59.9–61.2)	(60.0–61.6)	(78.0–81.0)		(74.6–77.5)	(75.3–76.7)
	2005-2009	19.9	61.1	22.4	26.9	68.1	68.1	84.0	8.4 (8.0-8.9)	87.3	77.0
		(19.6–20.2)	(60.8–61.5)	(22.1–22.8)	(25.8–28.0)	(67.6–68.6)	(67.5–68.7)	(83.0–85.0)		(86.5–88.1)	(76.4–77.7)
	2010-2014	25.1	68.9	27.2	31.3	71.8	71.1	86.6	10.5	89.9	77.3
		(24.8–25.4)	(68.6–69.2)	(26.8–27.6)	(30.3–32.4)	(71.4–72.2)	(70.6–71.7)	(85.8–87.5)	(10.0–10.9)	(89.2–90.5)	(76.6–78.0)

95% CI, 95% confidence interval. The estimates are from the CONCORD-3 (8). Age-standardized rates are calculated using the International Cancer Survival Standard weights (16).

136

					channe in all and	et an a la constant da da s	В					Character all services	diama ha sa sha da far
	Rank	Cancer 1990 China	Cancer 2017 Ch	nina F	Change in all-age	Change in age-standardized	Ranl	Cancer 1990 Japan		Cancer 2017 Japan	Rank	Change in all-age	Change in age-standardized
		Cancer 1990 China		illus i	UALY rates, % (UI)	LIALY rates, % (UI)		Country and a second part		The second		• DALY rates, % (UI)	DALY rates, % (OI)
	2	Liver cancer Stomach cancer	Tracheat, bronchus, an	id lung cancer	2 21.6 (11.3 to 35.0)	28.3 ( 34.4 to -10.0)	2	Stomach cancer Trachaal branchus and lung cancar		Tracheal, bronchus, and lung cancer	2	52.7 (47.9 to 57.8) 50.8 (45.6 to 56.7)	-14.5 (-17.2 to -11.6)
	2	Stomach cancer Teacheal branchus and lung cancer	Liver cancer		2 21.6 (11.5 (6 55.9)	-28.3 (-34.4 to -19.9) 50.2 ( 54.to .47.0)	2	Colon and reature cancer		Colon and rectum cancer	2	30.8 (43.0 to 30.7)	-11.1 (-14.3 (0 -7.2) \$7.6 ( \$0.0 to \$5.7)
	3	Frankageel engest	Econhegenlander		4 72(146te 01)	50.1 ( 54 1 49 46 4)	3	Liver senser		Demonstria annon	3	P1 A (75 5 to 97.7)	60(24 = 104)
	5	Laukamia	Colon and metum can	0.07	5 69 8 (49 5 to 86 6)	-19(-137 to 78)	-	Banaraatia cancar		Liver cancer		16.8 ( 20.0 to .8.5)	52 ( 59 5 to .47 2)
	6	Colon and rectum cancer	Breast cancer		6 649(42 to 90 1)	-24(-39,2 to 12.6)	6	Breast cancer	_	Breast cancer	6	50.6 (43.6 to 57.8)	13.8 (8.6 to 19.3)
	7	Other malignant neoplasms	Leukemia		7 -49.6 (-58.6 to -36.1)	-47.1 (-57.4 to -33.2)	7	Gallbladder and biliary tract cancer		Gallbladder and biliary tract cancer	7	16.2 (11.8 to 27.5)	=39.9 (=42.6 to =32.8)
	8	Breast cancer	Pancreatic cancer		8 137.7 (119.1 to 155.7)	32.8 (22.6 to 42.7)	8	Leukemia		Esonhageal cancer	8	29.6 (24.2 to 35.0)	-19.7 (-23.3 to -16.3)
	9	Brain and nervous system cancer	- Other malignant neon	lasms	9 73(-38 to 30.2)	-14.2 (-23.4 to 3.8)	9	Esonhageal cancer	2	Non-Hodekin lymnhoma	9	43 4 (36 7 to 50 3)	=16.8 (+21.6 to =12.1)
	10	Nasopharynx cancer	Brain and nervous sys	tem cancer	10 -8.4 (-28.9 to 33.6)	-22.1 (-39.8 to 13.8)	10	Other malignant neoplasms		Other malignant neoplasms	10	40.1 (10.2 to 62.4)	0.7 (-19.2 to 19.9)
	11	Cervical cancer	Non-Hodgkin lympho	ma	11 31.6 (20.0 to 44.2)	-3.9 (-12.8 to 5.2)	11	Non-Hodekin lymphoma	<u> </u>	Leukemia	11	-15.5 (-18.9 to -11.6)	-41.3 (-44.6 to -37.8)
	12	Non-Hodgkin lymphoma	- Cervical cancer		12 42.1 (-35.8 to 63.0)	-16.2 (-61.4 to -3.8)	12	Ovarian cancer	· /	Prostate cancer	12	143.4 (95.3 to 166.6)	11.3 (-9.2 to 24.2)
	13	Pancreatic cancer	Nasopharynx cancer		13 -24.8 (-31.6 to -16.1)	-53.5 (-57.6 to -48.2)	13	Cervical cancer	2	Bladder cancer	13	82.3 (76.1 to 89.2)	-11.5 (-15.0 to -7.7)
	14	Uterine cancer	Prostate cancer		14 98.9 (81.3 to 127.4)	0.4 (-8.0 to 13.2)	14	Prostate cancer		Ovarian cancer	14	12.4 (7.3 to 18.1)	-14.1 (-18.3 to -9.3)
	15	Prostate cancer	Ovarian cancer		15 123.5 (89.5 to 149.2)	35.8 (15.0 to 51.6)	15	Bladder cancer		Kidney cancer	15	77.4 (53.3 to 88.6)	5.5 (-7.4 to 13.1)
	16	Larynx cancer	Bladder cancer		16 39.2 (25.5 to 74.4)	-26.3 (-33.5 to -7.8)	16	Kidney cancer		Cervical cancer	16	1.4 (-3.1 to 7.0)	-17.1 (-20.9 to -12.4)
	17	Bladder cancer	Lip and oral cavity car	ncer	17 111.1 (92.4 to 128.5)	21.0 (10.5 to 30.9)	17	Brain and nervous system cancer	> _	Multiple myeloma	17	59.2 (46.0 to 83.0)	-10.5 (-18.9 to 7.1)
	18	Gallbladder and biliary tract cancer	- Larynx cancer		18 27.7 (18.8 to 36.3)	-29.3 (-34.2 to -24.7)	18	Multiple myeloma		Lip and oral cavity cancer	18	75.9 (69.2 to 84.4)	12.3 (7.8 to 18.3)
	19	Ovarian cancer	Gallbladder and biliar	y tract cancer	19 73.9 (15.3 to 104.4)	-4.7 (-37.7 to 12.5)	19	Uterine cancer		Uterine cancer	19	40.3 (32.8 to 48.0)	-2.1 (-7.6 to 3.8)
	20	Kidney cancer	Kidney cancer		20 70.4 (23.1 to 98.0)	18.4 (-14.6 to 37.0)	20	Lip and oral cavity cancer		Brain and nervous system cancer	20	67.1 (-18.0 to 96.0)	36 (-29.5 to 59.2)
	21	Lip and oral cavity cancer	Uterine cancer		21 -19.2 (-27.2 to -9.5)	-53.0 (-57.6 to -47.4)	21	Larynx cancer	N -	Other pharynx cancer	21	147.0 (133.7 to 165.1)	61.3 (52.5 to 73.9)
	22	Hodgkin lymphoma	Non-melanoma skin c	ancer	22 93.6 (73 to 112.2)	13.8 (2.0 to 24.4)	22	Thyroid cancer		Thyroid cancer	22	40.5 (33.8 to 48.5)	-18.7 (-23.3 to -13.2)
	23	Multiple myeloma	Multiple myeloma		23 63.2 (38.0 to 86.0)	1.2 (-15.4 to 12.6)	23	Other pharynx cancer	- >	Mesothelioma	23	99.5 (81.4 to 134.9)	20.3 (9.2 to 42.5)
	24	Non-melanoma skin cancer	Thyroid cancer		24 50.2 (33.9 to 70.0)	-7.7 (-18.2 to 4.1)	24	Nasopharynx cancer		Larynx cancer	24	-3.0 (-7.7 to 1.3)	-43.4 (-46.0 to -40.8)
	25	Thyroid cancer	Other pharynx cancer		25 37.3 (11.9 to 87.1)	-21.8 (-36.3 to 6.5)	25	Mesothelioma	-	Nasopharynx cancer	25	43.8 (35.6 to 53.9)	-1.4 (-7.0 to 5.7)
	26	Malignant skin melanoma	Malignant skin meland	oma	26 25.9 (-28.4 to 59.7)	-16.5 (-52.8 to 4.0)	26	Non-melanoma skin cancer		Non-melanoma skin cancer	26	79.9 (71.0 to 91.0)	-4.7 (-9.8 to 1.7)
	27	Other pharynx cancer	Mesothelioma		27 69.3 (17.6 to 134.8)	5.9 (-25.9 to 43.8)	27	Malignant skin melanoma		Malignant skin melanoma	27	45.0 (17.8 to 58.1)	5.8 (-13.9 to 15.8)
	28	Testicular cancer	Hodgkin lymphoma		28 -69.9 (-76.2 to -54.3)	-75.8 (-80.8 to -63.1)	28	Testicular cancer		Hodgkin lymphoma	28	3.9 (-20.8 to 17.0)	-14.0 (-33.4 to -3.0)
С	Rank				Change in all-age	Change in age-standardized	1						
		Cancer 1990 South Korea	Cancer 2017 So	uth Korea P	Rank DALY rates, % (UI)	DALY rates, % (UI)							
	1	Cancer 1990 South Korea Stomach cancer	Cancer 2017 So Tracheal, bronchus, an	uth Korea H nd lung cancer	Rank DALY rates, % (UI) 1 79.7 (65.0 to 96.9)	DALY rates, % (UI) -14.9 (-21.9 to -6.7)							
	1 2	Cancer 1990 South Korea Stomach cancer Liver cancer	Cancer 2017 So Tracheal, bronchus, an	uth Korea H nd lung cancer	Rank DALY rates, % (UI) 1 79.7 (65.0 to 96.9) 2 -4.0 (-21.0 to 19.7)	DALY rates, % (UI) -14.9 (-21.9 to -6.7) -51.6 (-60.0 to -39.7)							
	1 2 3	Cancer 1990 South Korea Stomach cancer Liver cancer Tracheal, bronchus, and lung cancer	Cancer 2017 So Tracheal, bronchus, an Liver cancer Stomach cancer	uth Korea H id lung cancer	Cank         DALY rates, % (UI)           1         79.7 (65.0 to 96.9)           2         -4.0 (-21.0 to 19.7)           3         -50.6 (-55.2 to -45.8)	DALY rates, % (UI) -14.9 (-21.9 to -6.7) -51.6 (-60.0 to -39.7) -74.9 (-77.2 to -72.5)							
	1 2 3 4	Cancer 1990 South Korea Stomach cancer Liver cancer Tracheal, bronchus, and lung cancer Leukemia	Cancer 2017 So Tracheal, bronchus, an Liver cancer Stomach cancer Colon and rectum can	uth Korea H nd lung cancer cer	Rank DALY rates, % (UI) 1 79.7 (65.0 to 96.9) 2 -4.0 (-21.0 to 19.7) 3 -50.6 (-55.2 to -45.8) 4 135.2 (111.4 to 159.1) 6 09.3 (10.1 to 19.1)	DALY rates, % (UI) -14.9 (-21.9 to -6.7) -51.6 (-60.0 to -39.7) -74.9 (-77.2 to -72.5) 11.7 (0.8 to 22.6)							
	1 2 3 4 5	Cancer 1990 South Korea Stomach cancer Liver cancer Tracheal, bronchus, and lung cancer Leukemia Colon and rectum cancer Collubed decarbolicies und cancer	Cancer 2017 So Tracheal, bronchus, an Liver cancer Stomach cancer Colon and rectum cancer Panetractic cancer	uth Korea H nd lung cancer cer	Rank DALY rates, % (UI) 1 79.7 (65.0 to 96.9) 2 -4.0 (-21.0 to 19.7) 3 -50.6 (-55.2 to -45.8) 4 135.2 (111.4 to 159.1) 5 98.3 (81.0 to 117.5) 6 95.6 (-23.5 tr 107.5)	DALY rates, % (UI) -14.9 (-21.9 to -6.7) -51.6 (-60.0 to -39.7) -74.9 (-77.2 to -72.5) 11.7 (0.8 to 22.6) -8.4 (-16.3 to 0.6) 20.0 25 to 14.8)							
	1 2 3 4 5 6 7	Cancer 1990 South Korea Stomach cancer Liver cancer Tracheal, bronchus, and lung cancer Leukemia Colon and rectum cancer Gallbladder and biliary tract cancer Bonneratic neuron	Cancer 2017 So Tracheal, bronchus, an Liver cancer Stomach cancer Colon and rectum can Pranceatic cancer Brast cancer	uth Korea H nd lung cancer	Bank         DAUry rates, % (UI)           1         79.7 (65.0 to 96.9)           2         -4.0 (-21.0 to 19.7)           3         -50.6 (-55.2 to -45.8)           4         135.2 (111.4 to 159.1)           5         98.3 (81.0 to 117.5)           6         85.6 (63.5 to 107.5)           7         20.8 (-3.1 to 51.0)	DALY rates \$6 (UI) -14.9 (-21.9 to -6.7) -51.6 (-60.0 to -39.7) -74.9 (-77.2 to -72.5) 11.7 (0.8 to 22.6) -8.4 (-16.3 to 0.6) 2.9 (-9.2 to 14.8) 4.6 (6 35 4 to -33.6)							
	1 2 3 4 5 6 7 8	Cancer 1990 South Korea Stomach cancer Liver cancer Tracheal, bronchus, and lung cancer Leukemia Colon and rectum cancer Gallbladder and biliary tract cancer Pancreatic cancer Broast cancer	Cancer 2017 So Tracheal, bronchus, an Liver cancer Stomach cancer Colon and rectum can Pancreatic cancer Breast cancer Gallbladder and billar U cutomis	uth Korea H ad lung cancer cer y tract cancer	Sank         DAUY rates, % (UI)           1         79.7 (65.0 to 96.9)           2         -4.0 (-21.0 to 19.7)           3         -50.6 (-55.2 to -45.8)           4         135.2 (111.4 to 159.1)           5         98.3 (81.0 to 117.5)           6         85.6 (63.5 to 107.5)           7         20.8 (-31.1 to 51.9)           8         -45.6 (51.7 to .37.7)	DALY rates, % (UI) -14.9 (-21.9 to -6.7) -51.6 (-60.0 to -39.7) -74.9 (-77.2 to -72.5) 11.7 (0.8 to 22.6) -8.4 (-16.3 to 0.6) 2.9 (-9.2 to 14.8) -46.6 (-58.4 to -33.6) -54 (-59.6 to -47.0)							
	1 2 3 4 5 6 7 8 9	Cancer 1990 South Korea Stomach cancer Liver cancer Liver cancer Tracheal, bronchus, and lung cancer Leukemia Colon and rectum cancer Galibladder and biliary tract cancer Breast cancer Other malienant nonalasms	Cancer 2017 So Tracheal, bronchus, an Stomach cancer Colon and rectum cann Pancreatic cancer Breast cancer Calibladder and billar Calibladder and billar Cher malinant non	uth Korea P di lung cancer cer y tract cancer	Sank         DALV rates, % (U)           1         79.7 (65.0 to 96.9)           2         -4.0 (-21.0 to 19.7)           3         -50.6 (-55.2 to -45.8)           4         135.2 (111.4 to 159.1)           5         98.3 (81.0 to 117.5)           6         85.6 (63.5 to 107.5)           7         20.8 (-51.7 to -38.7)           9         -27.2 (-42.0 to 14.2)	DALY rates, % (UI) -14.9 (-21.9 to -6.7) -51.6 (-6.00 to -39.7) -74.9 (-77.2 to -72.5) -11.7 (0.8 to 22.6) -84.4 (-16.3 to 0.6) 2.9 (-9.2 to 14.8) -46.6 (-58.4 to -33.6) -54.1 (-59.6 to -47.9) -44.9 (-58.5 to -17.8)				change			
	1 2 3 4 5 6 7 8 9	Cancer 1990 South Korea Somach cancer Liver cancer Liver cancer Lackenia Colon and rectum cancer Galbhadder and biliary tract cancer Pancratic cancer Brast cancer Other malignant neoplasms Foonbased Lonor	Cancer 2017 So Tracheal, bronchus, an Liver cancer Stomach cancer Colon and rectum can Pancratic cancer Galtbladder and billar Cleakemia Other malignant neopl Non-Hodekin lymphe	uth Korea P d lung cancer cer y tract cancer lasms ma	Bank         DALY rates, % (UI)           1         797. (65.0 to 96.9)           2         -4.0 (21.0 to 19.7)           3         -50.6 (-55.2 to 45.8)           4         135.2 (11.4 to 159.1)           5         98.3 (81.1 to 117.5)           7         20.8 (-3.1 to 15.7)           7         20.8 (-3.1 to 51.9)           8         -45.6 (-51.7 to -38.7)           9         -22.7 (-42.0 to 14.2)           10         54.7 (-67.70 72.3)	Charles (C)			No	change			
	1 2 3 4 5 6 7 8 9 10	Cancer 1990 South Korea Somach cancer Liver cancer Tacheal, bronchus, and lung cancer Leukemia Colon and rectum cancer Gallbhadder and biliary tract cancer Pancreatic cancer Other malignant neoplasms Esophageal cancer Cervical cancer	Cancer 2017 So Trackal, bronchus, an Liver cancer Stomach cancer Breast cancer Breast cancer Breast cancer Calibladder and bilar Culter malignant ncopi Non-Hodgkin lympho Sconbased cancer	uth Korea P d lung cancer cer y tract cancer lasms ma	Sank         DALY rates, % (UI)           1         79.7 (65.0 to 96.9)           2         -4.0 (21.0 to 19.7)           3         -50.6 (-55.2 to -45.8)           4         135.2 (11.1 4 to 159.1)           5         98.3 (81.0 to 117.5)           6         85.6 (63.5 to 107.5)           7         20.8 (-3.1 to 51.9)           8         -45.6 (-51.7 to -38.7)           9         -22.7 (-24.0 to 14.2)           10         54.7 (36.7 to 72.3)           11         23.6 (-33.3 to -13.9)	DALY rates % (UI) -14.9 (-21.9 to -6.7) -51.6 (-6.0 to -8.7) -74.9 (-77.2 to -72.5) -74.9 (-77.2 to -72.5) -74.9 (-77.2 to -72.5) -74.9 (-72.2 to -72.5) -74.9 (			No	change			
	1 2 3 4 5 6 7 8 9 10 11 11	Cancer 1990 South Korea Somach cancer Liver cancer Liver cancer Liver cancer Paneratic cancer Branstatic cancer Branstatic cancer Branst cancer Other malignant neoplasms Esophagael cancer Brani and nervous system cancer Brain and nervous system cancer	Cancer 2017 So Tracheal, bronchus, an Liver cancer Stomash cancer Pancraitic cancer Bracet cancer Galibladder and biliar Under maligaan noop Non-Hodgain lympho Besophageal cancer Brain and nervous so:	uth Korea P ad lung cancer cer y tract cancer lasms ma tem cancer	Sank         DAUY rates, % (U)           1         79.7 (65.0 to 965)           2         -4.0 (2.1 to 19.7)           3         50.6 (-55.2 to 45.8)           4         135.2 (11.1 4 to 159)           5         98.3 (81.0 to 117.5)           6         85.6 (63.5 to 107.5)           7         20.8 (-3.1 to 51.9)           8         -45.6 (-51.7 to -38.7)           9         -22.7 (-42.0 to 14.2)           10         54.7 (65.7 to 72.3)           11         -23.6 (-33.5 to -13.9)           2         -15.2 (-45.9 to 32.0)	DALY rates, % (UI) -14.9 (21.9 to -6.7) -14.9 (21.9 to -6.7) -31.6 (-6.00 to -3.9, 7) -74.9 (-7.12 to -7.2, 5) -11.7 (0.8 to -2.6) -8.4 (-16.3 to 0.6) -2.9 (-9.2 to 14.8) -46.6 (-5.8.4 to -3.3.6) -5.4 (-5.9.6 to -4.7.9) -44.9 (-5.8.5 to -17.8) -0.6 (-12.4 to 10.5) -64.2 (-68.8 to -59.6) -33.8 (-5.47, 70 11.5)			No	change			
	1 2 3 4 5 6 7 8 9 10 11 12 13	Cancer 1390 South Korea Somack cancer Liver cancer Tacheal, bronchus, and lung cancer Colon and rectum cancer Gallbladder and biliary tract cancer Pareratic cancer Breast cancer Other malignant nooplasms Esophageal cancer Cervical cancer Brain and nervous system cancer Non-Iedakin bruphoma	Cancer 2017 So Tracheal, brondha, and Liver cancer Somack cancer Colon and rectum can Parcetaic cancer Gibli Adder and Billian Other mailgana neophagal Cancer Brain and nervous sys Prostat cancer Brain and nervous sys	uth Korea P ad lung cancer cer y tract cancer lasms ma tem cancer	$\begin{array}{r llllllllllllllllllllllllllllllllllll$	DAU rates, % (UI) 149 (c1)9 (b = 67) 151 6 (c1)9 (b = 67) 151 6 (c1)9 (b = 67) 151 6 (b = 72) 117 (08 (b 22 6) 84 (-163 b 06) 29 (92 b 0148) 46 (c 58 x 10 b 05) 29 (92 b 0148) 46 (c 58 x 10 c 178) 44 (-163 b 0 c 178) 44 (-163 b 0 c 178) 45 (-124 b 0 - 178) 45 (-124 b			No	change nk increased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14	Cancer 1990 South Korea Somach cancer Liver cancer Tacheal, bronchus, and lung cancer Colon and rectam cancer Calibiadaer and bilary tract cancer Parcetaic cancer Parcetaic cancer Parcetaic cancer Door tangua cancer Boni and nervous system cancer Boni and nervous system cancer Non-Hodgin lymphoma Larnsx cancer	Cancer 2017 So Tracheal, borochus, and Liver cancer Somosk cancer Colon and rectum can Parcasi cancer Breast cancer Calkemia Other malignam neoph Brain and nervous sy Prostate cancer Kinkoy cancer	uth Korea P ad lung cancer cer y tract cancer lasms ma tem cancer	Bank         Dull' rates, % (U)           197.0550.0960)         197.0550.0960)           2-40.0210.017.7         3506.0552.10-4580           3-506.0552.10-4580         687.067.57           7         208.07.051.075.7           7         208.07.10-087.7           9         227.7(42.010.142.)           10         547.057.07.037.7           11         235.6(33.510-33.9)           12         152.2(55.02.80)           13         235.0(55.10.291.4)	$\begin{array}{l} DAUY rates, \% \left( UI \right) \\ = 149 (21) \times 0.67, \\ = 140 (21) \times 0.67, $			No Rar	change nk increased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	Cancer 1990 South Korea Somach cancer Liver cancer Tracheal, bronchus, and lung cancer Leadennia Catholader and history that the Panereatic cancer Breast cancer Other malignant neoplasms Sophagael cancer Corvial cancer Corvial cancer Drain and nervous system cancer Carvia Cancer Davis Sophagael Cancer Davis Sophagael Cancer Largins, Cancer Largins, Cancer Davis Sophagael Cancer Corvis Corvis	Cancer 2017 So Trackal, bondhus, and Liver cancer Colon and rectum can Proceedias cancer Colon and rectum can Proceedias cancer Colon and rectum can Other mailganan neop Non-Hodgkin tympion Sophagaal cancer Brain and nervous sys Kidney cancer Distancer cancer Distance cancer Dist	ad lung cancer cer y tract cancer lasms ma term cancer	Ank         DAUY rates, % (U)           107 (560 seq.))         107 (560 seq.))           2         400 (210 seq.))           3         506 (552 seq.458)           4         1352 (1114 seq.159.))           6         854 (635 seq.175.))           7         208 (631 seq.175.))           6         854 (635 rel.175.))           7         208 (631 seq.161.9)           8         456 (651 rel.35 seq.361.9)           9         227 (120 rel.161.2)           10         547 (367 rel.75.3)           12         252 (455 rel.260.)           13         2253 (455 rel.260.)           14         2325 (435 rel.260.)           13         2253 (455 rel.260.)           14         2323 (143 rel.104 rel.26.)           15         1530 (1194 rel.260.)	DALY rates, %; UJ) +14; 6(4) 00 - 367 +14; 6(4) 00 - 367 -14; 6(4) 00 - 367 -14; 6(4) 00 - 367 -14; 6(4) 00 - 367 -14; 6(4) 00 - 367 -24; 6(2) 00 - 275 -24; 7(2) 00 - 275 -25; 7(2) 00 - 255 -25; 7			No Rar	change nk increased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Cancer 1990 South Korea Somach cancer Liver cancer Liver cancer Liver cancer Liver cancer Colon and rectum cancer Colon and rectum cancer Basis cancer Brasset cancer Corvical cancer Corvical cancer Brain and nervous system cancer Non-Hodgkin hymbona Larpts, cancer Bladaer cancer Bladaer cancer	Cancer 2017 So Tracheal, borothus, and Liver cancer Colon and rectum cam Parcetic cancer Galanda Cancer Colon and rectum cam Parceta cancer Calcon and rectum cam Parceta cancer Calcon and rectum cam Parceta cancer Calcon and the calcon Parceta cancer Calcon and the calcon Parceta cancer Calcon and the calcon Parceta cancer Colorida cancer Corrical cancer	ad lung cancer ecer y tract cancer lasms ma tem cancer	Datk         DatkY         rates, % (U)           797.055.008.69)         2         40 (21.0 to 19.7)           3         306.6552.04538)         4           3         526.1522.04538)         4           3         526.1522.04538)         6           4         3352.011.44 to 159.1)         5           8         356.617.50         92.37 (42.014.32)           9         2.37 (42.014.32)         92.27 (42.014.32)           10         547.067.767.73         110           11         2.25 (42.56.012.01)         12           12         2.25 (42.56.012.01)         13           13         2.25 (42.56.012.01)         13           14         2.352 (43.10.291.41)         15           15         153.01 (19.4 to 19.2.01)         15	$\begin{array}{l} DAV \ matrix, S_{1}^{*} (U) \\ + 148 (c.21) 80.67) \\ + 148 (c.21) 80.67) \\ + 148 (c.21) 80.77) \\ + 749 (c.772.05) \\ + 11.7 (0.38) 0.22.6) \\ + 238 (c.163.30.66) \\ - 29 (c.22.10.14.8) \\ + 41 (c.48) 40.63 \\ + 41 (c.48) 40.6$			No Rar Bar	change nk increased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Cancer 1990 South Korea Somach cancer Liver cancer Tacheal, bronchus, and lung cancer Leukernia Caukernia cumo cancer Galbhadder and bhairy tract cancer Parecratic cancer Weast cancer Corvial cancer Koral and er Klein and nervous system cancer Klein and nervous system cancer Klein and nervous system cancer Wore Hodgkin lympioma Uprinte cancer Bladder cancer	Cancer 2017 So Trackal, bondhus, and Liver cancer Somak cancer Colon and rectum cam Partoralis cancer Calibladder and bilar Colder malignant neop Non-Holgkin tympion Sosphageal cancer Brain and nervous sy Prostac cancer Brain and nervous sy Prostac cancer Corrival cancer Corrival cancer Corrival cancer	id lung cancer cer y tract cancer lasms ma tem cancer	Daily         Transform           107         767           107         767           107         767           107         767           107         767           107         767           107         767           107         767           107         757           108         757           108         457           108         456           108         456           108         456           108         456           108         456           109         427           110         427           110         427           112         435           112         435           112         435           12         435           132         131           132         131           132         131           14         1323           16         348<<(429 to -260)	$\begin{array}{l} DAV \ marks, Sic (JJ)\\ + 149 \ c(21) 90 \ c(27) \\ + 149 \ c(21) 90 \ c(27) \\ + 149 \ c(21) 90 \ c(27) \\ + 120 \ c(27) \ c(27) \\ + 117 \ c(28) \ c(27) \\ + 115 \ c(28) \ c(28) \ c(28) \\ + 115 \ c(28) \ c(28) \ c(28) \ c(28) \\ + 115 \ c(28) \$			No Rar Rar	change 1k increased 1k decreased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Cancer 1990 South Korea Somach cancer Liver cancer Trackeal, bivenchas, and lung cancer Trackeal, bivenchas, and lung cancer Colon and rectum cancer Colon and rectum cancer Baseratic cancer Breast cancer Differ malignant neoplasms Other malignant neoplasms Cervical cancer Cervical cancer Userine cancer Userine cancer Userine cancer Ovarian cancer Ovarian cancer	Cancer 2017 So Trackal, bondbus, and Liver cancer Somak saarer and Pater and Soma Pater and Somar Somar Galbbadder and billar Exclosing Other mailganan theop Dephagoal cancer Brain and nervous sys Prostatic cancer Kidnys cancer Hidder cancer Hidder cancer Hidder cancer	d lung cancer ecer y tract cancer lasms ma tem cancer	Datk         DatkY         rates, % (U)           797.055.008.69)	$\begin{array}{l} DAV (rates, \%; UJ)\\ + 148 (>213 ws.7)\\ + 148 (>213 ws.7)\\ + 148 (>213 ws.7)\\ + 158 (>210 ws.7)\\ + 749 (>772 ws.725)\\ + 11.7 (038 ws.2.6)\\ + 258 (>210 ws.725)\\ + 11.7 (038 ws.2.6)\\ + 29 (>22 ws.138)\\ + 41 (>338 ws.36)\\ + 41 (>348 ws.36$			No Rar Rar	change nk increased nk decreased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19	Cancer 1990 South Korea Somach cancer Liver cancer Tracheal, bronchus, and lung cancer Leukernia Caukernia cumer active Caukernia cumer Paracetatic cancer Breast cancer Breast cancer Breast cancer Cervical cancer Brain and nervous system cancer Skoni-Jodgkin lymphoma Larphys.cancer Bladder cancer Divarian cancer Prostate cancer Prostate cancer Prostate cancer Prostate cancer Prostate cancer	Cancer 2017 So Trackal, bondhus, and Liver cancer Somak cancer Colon and rectum can Parceratic cancer Galibadeer and blian Coler maigaan neop Nos-Hodgkin tympke Esophageal cancer Brain and nervous sy Prostate cancer Brain and nervous sy Prostate cancer Corrival cancer Corrival cancer Hiddee cancer Thyroid cancer Thyroid cancer	uth Korea P d lung cancer cer y tract cancer lasms ma tem cancer	Datk         Datk Y rates, % (UI)           '27,050,0869)         '27,050,0869)           2         -40,021,061,07,03           3         -506,6552,045,83           4         -152,011,416,159,11           5         98,36,816,017,53           5         98,36,816,017,53           6         85,663,556,107,53           9         -22,71,42,016,142,107,38,71           9         -22,71,42,016,142,107,38,71           10         54,76,667,07,623,107,23,11           12         -152,463,107,21,001,241,11           14         -23,25,108,102,10,11           15         -45,66,151,102,141,102,144,11           16         -23,27,142,100,142,11           17         -152,463,102,104,11,102,144,11           18         +17,71,73,58,505,151,31,11           19         17,34,96,664,022,641,102,144,11	$\begin{array}{l} DAV \ (rates, \$; \ (U)) \\ + 449\ (c1)\ 290\ (c1)\ c30\ ($			No Rar Rar	change 1k increased 1k decreased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Cancer 1990 South Korea Somach cancer Liver cancer Tracheal, bronchus, and lung cancer Tracheal, bronchus, and lung cancer Colon and rectum cancer Colon and rectum cancer Brasis cancer Brasis cancer Company and the second second Brain and nervous system cancer Non-Hodgkin hymbrona Largyx, cancer Ulerinic cancer Bladder cancer Postale cancer Lip and oral cavity cancer Lip and oral cavity cancer	Cancer 2017 So Trackal, broadbus, and Liver cancer Somek cancer Colon and restorement Paras cancer Galbladder and bilar Heakemia Other malignant neopl Non-Hodgalh nymber Brain and nervous sys Brain and sys Brain and sys Brain and sys Brain an	eer lasms ma tem cancer heer heer heer heer heer heer heer h	Cank:         Daty Failers, % (UI)           197,650,0969)	$\begin{array}{l} DAU \ marks, S: (JJ)\\ + 149 \ (c13) \ 90 \ c-67)\\ + 149 \ (c13) \ 90 \ c-72.5\\ + 149 \ (c12) \ 90 \ c-72.5\\ + 117 \ (018 \ 022.6)\\ + 117 \ (018 \ 022.6)\\ + 117 \ (018 \ 022.6)\\ + 117 \ (018 \ 022.6)\\ + 117 \ (018 \ 022.6)\\ + 117 \ (018 \ 022.6)\\ + 117 \ (018 \ 022.6)\\ + 110 \ (018 \ 022.6)\\$			No Rar Rar	change 1k increased 1k decreased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Cancer 1990 South Korea Somach cancer Liver cancer Tracheal, bronchus, and lung cancer Leakenia Tacheal, a bronchus, and lung cancer Paneratic cancer Paneratic cancer Paneratic cancer Dother malignant neoplasms Sophagael cancer Bani and nervous system cancer Userine cancer Dienis cancer Dienis cancer Dienis cancer Dienis cancer Prostate cancer Prostate cancer Prostate cancer Prostate cancer Prostate cancer Prostate cancer Skidny cancer Non-melanoma skin cancer	Cancer 2017 So Trackal, bondhus, and Liver cancer Somak cancer Colon and rectum can Parceatic cancer Breast cancer Breast cancer Herest cancer Herest cancer Herest cancer Herest cancer Herest cancer Herest cancer Cologin hymphy Son-Holdgin hymphy Hymbi active Hymbi	eer sin	Datk         Daty Faces, % (UI)           797,055,008,69)	$\begin{array}{l} DAV \ (rates, \$; \ (U)) \\ + 449 \ (<1) \ 80^\circ, 80^\circ, 80^\circ, 71^\circ, 80^\circ, 80^$			No Rar Rar	change nk increased nk decreased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Cancer 1990 South Korea Somach cancer Liver cancer Tracheal, bronchus, and lung cancer Tracheal, bronchus, and lung cancer Colon and rectum cancer Colon and rectum cancer Brancratic cancer Bransteaucer Bransteaucer Bransteaucer Bransteaucer Ucerine cancer Ucerine cancer Distribution of the source Bladder cancer Prostate cancer Prostate cancer Prostate cancer Prostate cancer Noramelanoma akin cancer Non-melanoma akin cancer	Cancer 2017 So Tracking, bondbus, and Liver cancer Colon and restorm can Beneficial bondbus, and Color and restorm can Beneficial backet and bilitar Color mail guarant neop Non-Hodgkin Imple Posti cancer Benefagain Imple Color mail guarant neop Non-Hodgkin Imple Posti cancer Corvial cancer Kidnoy cancer Distance and Color mail guarant neop Non-Hodgkin Imple Corvial cancer Posti cancer Posti cancer Distance and Corvial cancer Distance and Corvial cancer Distance and Corvial cancer Distance and Corvial cancer Distance and Corvial cancer Distance and Color Corvial cancer Distance and Color Corvial cancer Distance and Color Corvial cancer Corvial cancer Corvial cancer Color planty cancer	eer lasms ma lement encer leer leer leer leer leer leer leer l	Cank         Daty Failers, % (UI)           197,650,0869)	$\begin{array}{l} DAV \ marks, S: (JJ)\\ + 149 \ (c1) \ 90 \ (c7)\\ + 149 \ (c1) \ 90 \ (c7)\\ + 149 \ (c1) \ 90 \ (c7)\\ + 100 \ (c1) \ (c7)\\ + 117 \ (c7) \ (c7)\\ + 110 \ (c7) \$			No Rar Rar	change 1k increased 1k decreased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Cancer 1990 South Korea Somach cancer Liver cancer Liver cancer Liver cancer Liver cancer Colon and rectum cancer Colon and rectum cancer Basis cancer Brass cancer Corvical cancer Corvical cancer Corvical cancer Corvical cancer Brain and nervous system cancer Mon-Hodgkin hymbona Larpts, cancer Bladder cancer Divatice cancer Divatice cancer Lip and on Lavyty cancer Lip and on Lavyty cancer Multiple myolema Nusopharyns, cancer	Cancer 2017 So Trackel, bondbus, and Liver cancer Somak saacer and Pancraite cancer Pancraite cancer Galibiader and billar Calibiader and billar Calibiader and billar Calibiader and billar Calibiader and billar Calibiader and billar Calibiader and billar Some folgien brenden Some f	d lung cancer d lung cancer correst lasma ma cancer correst lasma ma cancer lasma necer cancer correst lasma cance	$\begin{array}{r c c c c c c c c c c c c c c c c c c c$	$\begin{array}{l} DAV \ (rates, §: (U))\\ + 149 \ (<1) 390 \ (<1) 300 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1) 371 \ (<1$			No Rar Rar	change 1k increased 1k decreased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Cancer 1990 South Korea Somach cancer Liver cancer Tracheal, bronchus, and lang cancer Coderna Tracheal, bronchus, and lang cancer Cancer Banteratic cancer Breast cancer Carvical cancer Carvical cancer Carvical cancer Carvical cancer Carvical cancer Carvical cancer Dens Hoghinh proghoma Larynx cancer Ulerine cancer Bidder cancer Prostate cancer Prostate cancer Prostate cancer Prostate cancer Prostate cancer Stroster State Cancer Not-melanoma kin cancer Not-melanoma kin cancer Natopher planynx cancer	Cancer 2017 So Trackal, bondhus, and Liver cancer Colon and rectum can Proceedings of the Proceedings of the Colon and rectum can Proceedings of the Colon and rectum can Proceedings of the Color mail game of the Color of	d lung cancer d lung cancer d lung cancer h lung cancer h lung cancer lasms ma h lung cancer lasms h lung cancer h	$\begin{array}{r c c c c c c c c c c c c c c c c c c c$	$\begin{array}{l} DAV \ marks, S: (JI)\\ + 149 \ (c1) \ 90 \ (c7)\\ + 149 \ (c1) \ 90 \ (c7)\\ + 149 \ (c1) \ 90 \ (c7)\\ + 100 \ (c1) \ 90 \ (c7)\\ + 100 \ (c1) \ 90 \ (c7)\\ + 100 \ (c1) \ 90 \ (c1) \ 90 \ (c1)\\ + 100 \ (c1) \ 90 \ (c1) \ 90 \ (c1)\\ + 100 \ (c1) \ 90 \ (c1) \ 90 \ (c1)\\ + 100 \ (c1) \ 90 \ (c1) \ $			No Rar Rar	change 1k increased 1k decreased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 9 20 21 22 23 24 25 5	Cancer 1990 South Korea Somach cancer Liver cancer Trackeal, Wonchas, and Jung cancer Trackeal, Wonchas, and Jung cancer Trackeal, Wonchas, and Jung Cancer Panereatic cancer Flexast cancer Flexast cancer Brain and nervous system cancer Non-Hodgkin Dynobran Laryns, cancer Lorixic cancer Dorarian cancer Horina cancer Dorarian cancer Dorata cancer Lip and on leavity cancer Dorata cancer Multiple rayoloma Nasopharyns, cancer Other playus, cancer Other playus, cancer	Cancer 2017 So Trackal, bondbus, and Liver cancer Somak saarer and Pateria and Somak Somer Paterials and Somer Paterials and Somer Galbbadder and Billar Exployaged amore Brain and nervous sys Prostate cancer Brain and nervous sys Brain and nervous sys Brain and nervous sys Differ planyte cancer Differ planyte and Differ planyte and Di	di lung cancer e e e e e e e e e e e e e e e e e e	$\begin{array}{r c c c c c c c c c c c c c c c c c c c$	$\begin{array}{l} DAY \ rates, $5:\ (JI)\\ +149\ (=1390.67)\\ +149\ (=1390.67)\\ +149\ (=1390.67)\\ +117\ (Ob\ 022.6)\\ +117\ (Ob\ 02.6)\\ +117\ (Ob\ 02.6)\ +117\ (Ob\ 02.6)\\ +117\ (Ob\ 02.6)\ +117\ (Ob\ 0$			No Rar Rar	change nk increased nk decreased			
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 7 18 19 20 21 22 23 24 25 26 6 7	Cancer 1990 South Korea Somach cancer Liver cancer Tracheal, bronchus, and lung cancer Loukerna Cankerna Berneratic cancer Breast cancer Drast cancer Breast cancer Carvical cancer Drast and erer Drast cancer Drast and erer Drast cancer Drast cancer Drast cancer Drast cancer Drast cancer Drast cancer Diadort cancer Diadort cancer Diadort cancer Diadort cancer Notatic cancer Notatic cancer Notatic cancer Notatic cancer Notation cancer Notation cancer Natific mytomer Natopharynx cancer Dirother pharynx cancer Dirother pharynx cancer Dirother Cancer Maiganat akin melanoma	Cancer 2017 So Trackal, bondhus, and Liver cancer Colon and rectum can Proceedings of the Proceedings of the	di lung cancer di lung cancer uy tract cancer lasms ma leem cancer ancer sma	$ \begin{array}{r c c c c c c c c c c c c c c c c c c c$	$\begin{array}{l} DAU \ {mars}  S_{1} \ (U) \\ + 149 \ (c1)  200 \ (c7) \\ + 149 \ (c1)  200 \ (c7) \\ + 149 \ (c1)  200 \ (c7) \\ + 149 \ (c7)  200 \ (c7) \\ + 117 \ (c7) \ (c7) \\ + 118 \ (c7) \ (c7) \ (c7) \\ + 118 \ (c7) \ (c7) \ (c7) \\ + 118 \ (c7) \ (c7) \ (c7) \ (c7) \\ + 118 \ (c7) \ $			No Rar Rar	change 1k increased 1k decreased			
	1 2 3 4 4 5 6 7 7 8 9 9 10 11 11 23 14 15 16 17 18 9 20 21 22 23 24 22 22 22 22 22 7 27	Cancer 1990 South Korea Somach cancer Liver cancer Tracheal, brownchus, and lung cancer Tracheal, brownchus, and lung cancer Brancratic cancer Brancratic cancer Branst and rectum cancer Other malignant nooplasms Differ malignant nooplasms Brain and nervous system cancer Non-Hodgkin hymphoma Larynx, cancer Uperince cancer Disdate cancer Disdate cancer Disdate cancer Non-melanoma skin cancer Non-melanoma skin cancer Non-melanoma skin cancer Malighen mytoma Other playnx, cancer Uprovida cancer Malighen you cancer Malighen you cancer Malighen skin melanoma Kin cancer Malighen skin melanoma Kin cancer	Cancer 2017 So Trackal, brondbus, and Liver cancer Somek cancer Colon and restoreman Colon and restoreman Colon and restoreman Colon and restoreman Colon and restoreman Colon and restoreman Cologial in hymo Postal cancer Cologial in hymo Postal cancer Cologial in hymo Postal cancer Cologial in hymo Postal cancer Color and another Color and another Color and cancer Color and cancer Color planys cancer Color planys cancer Color planys cancer Nasopharys cancer	d hang cancer d hang cancer gramma term cancer ancer ancer ancer ancer	$ \begin{array}{r c c c c c c c c c c c c c c c c c c c$	$\begin{array}{l} \text{DAV} \ \text{track}, \ & \text{St}, \ \text{UI} \\ \text{i} \ \text{def} \ (213) \ \text{oc} \ \text{def}, \ \text{oc} \ \text{oc} \ \text{oc} \ \text{oc} \ \text{def}, \ \text{def} \ \text{def}, \ \text{def} \ \text{def}, \ \text{def} \ \text{def}, \ \text{def} \ \text{def}, \$			No Rar Rar	change 1k increased 1k decreased			
	1 2 3 4 4 5 6 7 8 9 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 8	Cancer 1990 South Korea Somach cancer Liver cancer Liver cancer Liver cancer Liver cancer Liver cancer Colon and rectum cancer Caliblader and histing tract cancer Paracreatic cancer Doer malignant hotphasms Esciphageal cancer Corvical cancer Corvical cancer Doer malignant hotphasms Esciphageal cancer Corvical cancer Bladaer cancer Bladaer cancer Bladaer cancer Divastac cancer Norstata cancer Natopharyn cancer Norst place y normer Natopharyn cancer Natopharyn cancer Norst place y normer Norst place y normer Normer Norst place y normer Nor	Cancer 2017 So Trackal, bondhus, and Liver cancer Colon and rectum can Parcetails cancer Colon and rectum can Parcetails cancer Callbladder and bilar Coldgrin tymbo Footback (Callbadder and Callbadder Sophageal cancer Brain and nervous sy Prostate cancer Brain and nervous sy Prostate cancer Crivials cancer Brain and nervous sy Prostate cancer Crivials cancer Brain and nervous sy Prostate cancer Brain and nervous sy Prostate cancer Crivials cancer Brain and nervous sy Prostate cancer Brain and nervous sy Brain and nervous sy Bra	di hung cancer di hung cancer cer y tract cancer tem cancer ancer ancer ancer	$ \begin{array}{r c c c c c c c c c c c c c c c c c c c$	$\begin{aligned} DAV (rates, §: (U)) \\ + 149 (c1) 290 (c2) (c3) (c3) (c3) (c3) (c3) (c3) (c3) (c3$			No Rar Rar	change 1k increased 1k decreased			

**Figure 4** Rank changes in disability-adjusted life years (DALYs) attributable to cancers and percentage change in all age and agestandardized DALY rates in China (A), Japan (B), and South Korea (C) from 1990 to 2017. The estimates used to generate this figure were from the Institute for Health Metrics and Evaluation (IHME) website (7). Age-standardized rates were calculated using the GBD reference population (18).

South Korea (*Figure 4*). But *Table 3* indicates that the ASIR of lung cancer decreased constantly among males in South Korea. *Table 4* shows the age-standardized 5-year cancer survival rates in China, Japan, and South Korea from 2000 to 2014. Survival trends were generally increasing in common types of cancers in the three countries, except for the pancreas cancer survival rate in China.

China, Japan, and South Korea experienced significant downward trends in ASIR and DALYs for liver cancer. As for stomach cancer, declining incidence was also observed in China and Japan, and the incidence decreased but not statistically significant in South Korea (*Table 3*). For Japan and South Korea, stomach cancer declined from being the leading cause of all-age DALYs in 1990 to the third in 2017 (*Figure 4B,C*). The trend analysis indicated that the incidence of esophageal cancer decreased in China and South Korea but increased in Japan. The burden of colorectal cancer in China, Japan, and South Korea has increased over the past several decades. In regard with prostate and thyroid cancers, a constantly growing burden was observed in China, Japan, and South Korea. Besides, there was an alarming trend to increase in breast cancer incidence rates in the three countries.

#### Discussion

In this study, we performed a comprehensive epidemiological analysis of cancer burden and trends in China and compared the differences between China, Japan and South Korea using high-quality data. We found that China was faced with a rising burden of colorectal, prostate, and breast cancers as well as a heavy burden of lung and upper digestive tract cancers. Compared with Japan and South Korea, China has higher ASMR and DALY rates.

China had a higher ASMR and a relatively lower ASIR for all cancers than Japan and South Korea. Several reasons could explain the seemingly paradoxical situation. Firstly, the significant difference in the composition of incident cancers could result in the higher mortality rate in China. The most common incident cancer was lung cancer in China rather than colorectal cancer, which ranked first for ASIR in Japan and South Korea. The ASIR of lung cancer with a poor prognosis, was higher in China (35.1 per 100,000) than that in Japan (27.5 per 100,000) and South

Korea (27.8 per 100,000). In addition, prostate cancer with a low fatality rate ranked fourth in Japanese males and South Korean males, while it fell outside the first five common cancers for ASIR in Chinese males. Secondly, China had lower survival rates of thyroid, breast, colorectal, prostate and stomach cancers. One possible explanation is that higher screening uptake rates in Japan and South Korea may drive the inflation of cancer incidence rates and promote the early detection (4,20). For example, endoscopic screening performed in Japan and South Korea (20,21) may bring about the higher survival rates of stomach cancer. Poor access to cancer care in China also could result in the disparities (4).

Concerning the time trends, similar to previous studies (22,23), we found that China, Japan, and South Korea experienced significant downward trends in the burden of liver and stomach cancers. This trend has been explained by a series of lifestyle changes and public health interventions. For example, the spread of hepatitis B virus vaccination (5,24) and reduced aflatoxin exposure (25) are thought to have contributed to the reduction of liver cancer in China. In Japan, it might be associated with the reduced hepatitis C virus infection (26,27). But the increasing prevalence of obesity and diabetes presents a threat to the favorable trend (28). For stomach cancer, the decreasing prevalence of Helicobacter pylori infection, improved living conditions, and better food preservation practices lead to the declining rates (29). Similar to our analysis, an updated analysis from the National Cancer Center of Japan reported an increase of age-standardized esophageal cancer incidence. But the declining mortality was observed (11). Reasons for this divergent trend have yet to be identified. Endoscopic screening conducted in Japan may have an influence.

Another notable sign for optimism is that lung cancer incidence for males in South Korea has been decreasing constantly in recent years, which reflects a corresponding decline in the smoking prevalence in South Korea. Smoking prevalence among South Korean males dropped from 71.7% in 1992 to 39.7% in 2016 (30). Tobacco control can prevent lung cancer effectively. Nevertheless, though some progress in tobacco control has been made (31,32), China still faces high smoking rates. The National Health Service Survey conducted in 2013 found that more than 45% of Chinese males are current smokers (33). Also, faltering tobacco control policies is criticized in Japan (34). South Korea serves as an example of tobacco control to China and Japan (35). Stronger tobacco control is urgently needed such as increasing tobacco excise taxes and introducing a national smoke-free law.

In our analysis, colorectal, prostate and breast cancers tended to be more common in China, Japan, and South Korea. But according to the latest data from national cancer registries, colorectal cancer incidence and mortality have shown signs of declining in Japan and South Korea (11,12,36). The long-standing national screening programs may have an impact (37-39). Another notable aspect is that Japan and South Korea set up institutions responsible for providing comprehensive cancer information to enhance public awareness (40,41). The rapid rise of prostate cancer incidence could be explained by the widespread prostatespecific antigen testing. Besides, prostate cancer incidence and mortality in Japan and South Korea has seemingly plateaued in recent years (11,36). The rapidly increasing incidence of thyroid cancer in South Korea (42) sounded the alarm that screening also has the potential to promote overdiagnosis. Limited knowledge could explain the rapid increase in female breast cancer. This trend may reflect a collaboration of changed environmental factors, including the delay of childbearing, increases in the levels of obesity, and the spread of breast cancer screening (3).

Our work has several limitations. First, the comparison of estimates in different countries might be compromised because of variations in data collection and reporting systems across countries. Second, our trend analysis was only based on several registries due to insufficient data availability. The observed trends may not represent national profiles. Moreover, trends in the recent ten years could not be evaluated owing to unavailable up-to-date data. It is required to update the analysis based on more contemporary data and use more compressive analysis such as age-period-cohort analysis.

#### Conclusions

At the transition cancer stage, China still had a heavy burden of lung and upper digestive tract cancers and faced a rising burden of colorectal, prostate, and breast cancers. China, Japan, and South Korea shared similar cancer profiles and time trends. Although the strategies established in Japan and South Korea should be adapted to the specific contexts of China, we could draw some useful lessons. Compared with Japan and South Korea, China had higher age-standardized cancer mortality and DALY rates but lower incidence. Relatively lower mortality and favorable trends of colorectal and lung cancers appeared in Japan or South Korea indicated the effectiveness of screening and tobacco control. Improvement in the current tobacco control policy and cancer screening systems may contribute to cancer control in China. Also, given huge geographic disparities in cancer burden across China, evidence-based approaches are needed for cancer control programs, and tailored to local profile and population risk.

# Acknowledgements

This study was supported by the National Key R&D Program of China (No. 2018YFC1313100); Sanming Project of Medicine in Shenzhen (No. SZSM201911015); CAMS Innovation Fund for Medical Sciences (CIFMS) (No.2016-I2M-2-004).

# Footnote

*Conflicts of Interest*: The authors have no conflicts of interest to declare.

# References

- 1. World Health Organization. Global Health Observatory. 2020. Geneva. Available online: https:// www.who.int/data/gho
- Zheng R, Gu X, Li X, et al. Analysis on the trend of cancer incidence and age change in cancer registry areas of China, 2000 to 2014. Zhonghua Yu Fang Yi Xue Za Zhi (in Chinese) 2018;52:593-600.
- 3. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
- 4. Goss PE, Strasser-Weippl K, Lee-Bychkovsky BL, et al. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol 2014;15:489-538.
- Jun JK, Yoo K-Y. National Cancer Control in Korea. In: Withers M, McCool J, eds. Global Health Leadership: Case Studies From the Asia-Pacific. Cham: Springer International Publishing, 2019.
- 6. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. 2018. Lyon, France. Available online: https://gco.iarc.fr/today
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2017(GBD 2017) Results. 2018. Available online: http://ghdx.healthdata. org/gbd-results-tool
- 8. Allemani C, Matsuda T, Di Carlo V, et al. Global

surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet 2018;391:1023-75.

- 9. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115-32.
- Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi (in Chinese) 2019;41:19-28.
- 11. Katanoda K, Hori M, Matsuda T, et al. An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013. Jpn J Clin Oncol 2015;45:390-401.
- 12. Center for Cancer Control and Information Services. Cancer Statistics in Japan. 2019. Available online: https://ganjoho.jp/en/professional/statistics/table\_do wnload.html
- Ministry of Health and Welfare. Cancer Registration Statistics. 2020. Available online: http://kosis.kr/eng/
- Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941-53.
- Ferlay J, Colombet M, Bray F. Cancer Incidence in Five Continents, CI5plus: IARC CancerBase No. 9. 2018. Lyon, France. Available online: http://ci5.iarc.fr
- 16. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 2004;40:2307-16.
- GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392: 1859-22.
- GBD 2017 Mortality Collaborators. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392:1684-735.
- 19. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-51.
- 20. Suh M, Song S, Cho HN, et al. Trends in Participation Rates for the National Cancer Screening Program in Korea, 2002-2012. Cancer Res Treat 2017;49:

798-806.

- 21. Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol 2014;49:1-8.
- 22. Wu J, Yang S, Xu K, et al. Patterns and Trends of Liver Cancer Incidence Rates in Eastern and Southeastern Asian Countries (1983-2007) and Predictions to 2030. Gastroenterology 2018;154: 1719-28.
- Arnold M, Park JY, Camargo MC, et al. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut 2020 Jan 30. [Epub ahead of print]
- 24. Tanaka M, Katayama F, Kato H, et al. Hepatitis B and C virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol 2011;21:401-16.
- Sun Z, Chen T, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis 2013;34: 1800-5.
- 26. Tanaka J, Akita T, Ohisa M, et al. Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat 2018;25:363-72.
- 27. Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35:2155-66.
- 28. Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology 2018;67:600-11.
- 29. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017;153:420-9.
- 30. Chang Y, Kang HY, Lim D, et al. Long-term trends in smoking prevalence and its socioeconomic inequalities in Korea, 1992-2016. Int J Equity Health 2019;18:148.

**Cite this article as:** Sun D, Cao M, Li H, He S, Chen W. Cancer burden and trends in China: A review and comparison with Japan and South Korea. Chin J Cancer Res 2020; 32(2):129-139. doi: 10.21147/j.issn.1000-9604.2020.02.01

- 31. Lin H, Chang C, Liu Z, et al. Subnational smoke-free laws in China. Tob Induc Dis 2019;17:78.
- 32. Li X, Galea G. Healthy China 2030: an opportunity for tobacco control. Lancet 2019;394:1123-5.
- 33. Wang M, Luo X, Xu S, et al. Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from 2003 to 2013. Lancet Respir Med 2019;7:35-45.
- 34. Sobue T. ED12.05 Tobacco Control Policies in Japan. J Thorac Oncol 2017;12:S54-S56.
- 35. Levy DT, Cho SI, Kim YM, et al. SimSmoke model evaluation of the effect of tobacco control policies in Korea: the unknown success story. Am J Public Health 2010;100:1267-73.
- Jung KW, Won YJ, Kong HJ, et al. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016. Cancer Res Treat 2019;51: 417-30.
- Keum N, Giovannucci E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol 2019; 16:713-32.
- Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut 2015;64:1637-49.
- 39. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017;66:683.
- 40. Kye SY, Lee MH, Yoo J, et al. Factors affecting satisfaction with cancer information provided through the social networking services of the National Cancer Information Center in Korea. Epidemiol Health 2017;39:e2017057.
- 41. Okuhara T, Ishikawa H, Urakubo A, et al. Cancer information needs according to cancer type: A content analysis of data from Japan's largest cancer information website. Prev Med Rep 2018;12:245-52.
- Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic" — screening and overdiagnosis. N Engl J Med 2014;371:1765-7.

	vobol -	Condor	AII					-	Rank				
Contrict	lindex	Gender	cancers	1st	2nd	3rd	4th	5th	6th	7th	8th	9th	10th
Japan	Incidence	Both	248.0	Breast	Colorectum	Prostate	Lung	Stomach	Corpus uteri	Cervix uteri	Pancreas	Ovary	Bladder
				57.6	38.9	35.4	27.5	27.5	15.1	14.7	9.7	9.5	8.7
		Male	285.9	Colorectum	Lung	Stomach	Prostate	Bladder	Liver	Pancreas	Kidney	Esophagus	NHL
				49.1	41.4	40.7	35.4	15.1	12.3	11.7	11.2	9.3	8.7
		Female	220.5	Breast	Colorectum	Stomach	Lung	Corpus uteri	Cervix uteri	Thyroid	Ovary	Pancreas	NHL
				57.6	29.6	16.0	15.6	15.1	14.7	11.2	9.5	7.7	6.1
	Mortality	Both	85.2	Lung	Colorectum	Stomach	Breast	Pancreas	Liver	Prostate	Gallbladder	Ovary	Esophagus
				16.2	12.0	9.5	9.3	7.8	5.4	4.4	3.3	3.3	2.8
		Male	111.9	Lung	Colorectum	Stomach	Pancreas	Liver	Esophagus	Prostate	Gallbladder	NHL	Leukemia
				26.5	15.2	14.3	9.5	8.6	5.1	4.4	4.2	3.5	3.1
		Female	64.3	Breast	Colorectum	Lung	Pancreas	Stomach	Ovary	Liver	Cervix uteri	Gallbladder	NHL
				9.3	9.2	7.8	6.2	5.6	3.3	2.7	2.7	2.5	1.9
South Korea	Incidence	Both	313.5	Thyroid	Breast	Colorectum	Stomach	Prostate	Lung	Liver	Cervix uteri	NHL	Kidney
				60.7	59.8	44.5	39.6	36.2	27.8	17.3	8.4	8.0	7.9
		Male	332.1	Colorectum	Stomach	Lung	Prostate	Liver	Thyroid	Kidney	NHL	Pancreas	Gallbladder
				59.5	57.8	41.7	36.2	27.7	21.8	11.5	0.6	8.7	8.4
		Female	310.6	Thyroid	Breast	Colorectum	Stomach	Lung	Cervix uteri	Liver	Corpus uteri	NHL	Ovary
				100.5	59.8	31.3	23.5	17.2	8.4	8.2	7.8	7.1	6.5
	Mortality	Both	80.7	Lung	Liver	Colorectum	Stomach	Pancreas	Breast	Prostate	Gallbladder	Ovary	Leukemia
				18.1	11.8	8.7	7.0	6.1	6.0	4.7	4.1	2.4	2.3
		Male	115.2	Lung	Liver	Colorectum	Stomach	Pancreas	Gallbladder	Prostate	Esophagus	Leukemia	NHL
				31.4	19.5	11.8	10.0	7.6	5.0	4.7	3.3	3.0	2.8
		Female	55.0	Lung	Colorectum	Breast	Liver	Pancreas	Stomach	Gallbladder	Ovary	Cervix uteri	Leukemia
				8.2	6.3	6.0	5.2	4.9	4.8	3.4	2.4	2.0	1.7
NHL, non method a	-Hodgkin I nd the wor	ymphoma d standar	t. The es d popula	stimates are fi ition.	rom Global C	ancer Obser	vatory 201	8, IARC, 2	018 (6). Age-	standardized	d rates are c	alculated usir	ig the direct

								-					
			cancers	1st	2nd	3rd	4th	5th	6th	7th	8th	9th	10th
Japan 4	All age rates	Both	5,123.6	Lung	Colorectum	Stomach	Pancreas	Liver	Breast	Gallbladder	Esophagus	Other	Prostate
				933.5	709.5	656.0	411.9	386.8	275.6	222.4	177.2	167.3	165.3
		Male	6,404.7	Lung	Stomach	Colorectum	Liver	Pancreas	Prostate	Esophagus	Gallbladder	Other	NHL
				1,400.2	936.8	859.3	562.2	472.1	339.2	312.4	252.8	197.0	191.0
		Female	3,906.3 C	Solorectum	Breast	Lung	Stomach	Pancreas	Liver	Gallbladder	Ovarian	Other	Cervix
				567.2	534.0	490.1	389.1	354.7	220.2	193.6	171.3	139.2	137.6
~ _	Age-standardize ates	d Both	2,285.5	Lung	Colorectum	Stomach	Pancreas	Liver	Breast	Other	Leukemia	Gallbladder	<ul> <li>Esophagus</li> </ul>
				372.7	303.9	275.3	172.2	158.6	155.4	106.7	93.0	82.5	77.8
		Male	2,907.5	Lung	Stomach	Colorectum	Liver	Pancreas	Esophagus	Other	Prostate	Leukemia	Gallbladder
				590.2	409.1	391.8	250.4	213.5	141.1	125.9	125.5	112.1	104.4
		Female	9.1,768.6	Breast	Colorectum	Lung	Stomach	Pancreas	Ovarian	Other	Cervix	Liver	Leukemia
				303.8	225.9	186.5	160.6	133.9	98.5	89.6	85.1	75.3	75.1
South Korea	VII age rates	Both	3,727.0	Lung	Liver	Stomach	Colorectum	Pancreas	Breast	Gallbladder	Leukemia	Other	NHL
				689.1	605.7	473.6	388.8	227.5	201.7	165.9	116.3	106.0	90.8
		Male	4,728.6	Lung	Liver	Stomach	Colorectum	Pancreas (	Gallbladder	Prostate	Leukemia	Esophagus	Other
				1,002.3	954.8	659.8	480.0	264.0	188.8	166.9	136.3	136.1	119.7
		Female	\$ 2,710.2	Breast	Lung	Colorectum	Stomach	Liver	Pancreas	Gallbladder	Ovarian	Cervix	Leukemia
				404.0	371.2	296.2	284.7	251.3	190.5	142.6	112.2	109.2	95.9
~ ~	Age-standardize ates	d Both	2,386.1	Lung	Liver	Stomach	Colorectum	Pancreas	Breast	Gallbladder	Leukemia	Other	Brain, CNS
				421.7	371.5	297.4	242.1	139.2	128.4	102.1	101.2	83.6	65.4
		Male	3,269.5	Lung	Liver	Stomach	Colorectum	Pancreas (	Gallbladder	Prostate	Leukemia	Other	Esophagus
				688.5	614.9	444.8	329.0	174.9	130.9	128.3	121.4	97.6	89.5
		Female	9 1,669.7	Breast	Lung	Stomach	Colorectum	Liver	Pancreas	Leukemia	Gallbladder	Other	Cervix
				250.1	210.6	175.1	170.8	145.2	107.3	81.9	78.8	71.2	6.9.9
				451.8	253.0	251.6	235.5	168.9	146.6	132.3	117.9	107.6	102.3